This content is in French.
Advanced hepatocellular carcinoma in Europe: a rapidly evolving treatment landscape
27 octobre 2026
Immunotherapy has reshaped first-line treatmentTreatment of unresectable and advanced hepatocellular carcinoma (HCC) has changed substantially over the past decade. For many years, sorafenib was the principal systemic option, with median overall survival generally limited to around 12–13 months. The introduction of immune checkpoint inhibitor-based combinations has shifted expectations, with conte
Immunotherapy has reshaped first-line treatment
Treatment of unresectable and advanced hepatocellular carcinoma (HCC) has changed substantially over the past decade. For many years, sorafenib was the principal systemic option, with median overall survival generally limited to around 12–13 months. The introduction of immune checkpoint inhibitor-based combinations has shifted expectations, with contemporary phase III trials reporting median overall survival of approximately 16–23 months.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
